Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 3
2008 3
2009 8
2010 5
2011 7
2012 8
2013 5
2014 11
2015 9
2016 9
2017 9
2018 2
2019 5
2020 4
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

79 results
Results by year
Filters applied: . Clear all
Page 1
Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma.
Sun J, Muz B, Alhallak K, Markovic M, Gurley S, Wang Z, Guenthner N, Wasden K, Fiala M, King J, Kohnen D, Salama NN, Vij R, Azab AK. Sun J, et al. Among authors: azab ak. Cancers (Basel). 2020 Jan 28;12(2):305. doi: 10.3390/cancers12020305. Cancers (Basel). 2020. PMID: 32012878 Free PMC article.
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.
Ghobrial IM, Liu CJ, Zavidij O, Azab AK, Baz R, Laubach JP, Mishima Y, Armand P, Munshi NC, Basile F, Constantine M, Vredenburgh J, Boruchov A, Crilley P, Henrick PM, Hornburg KTV, Leblebjian H, Chuma S, Reyes K, Noonan K, Warren D, Schlossman R, Paba-Prada C, Anderson KC, Weller E, Trippa L, Shain K, Richardson PG. Ghobrial IM, et al. Among authors: azab ak. Am J Hematol. 2019 Nov;94(11):1244-1253. doi: 10.1002/ajh.25627. Epub 2019 Oct 4. Am J Hematol. 2019. PMID: 31456261 Free article. Clinical Trial.
Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma.
Federico C, Alhallak K, Sun J, Duncan K, Azab F, Sudlow GP, de la Puente P, Muz B, Kapoor V, Zhang L, Yuan F, Markovic M, Kotsybar J, Wasden K, Guenthner N, Gurley S, King J, Kohnen D, Salama NN, Thotala D, Hallahan DE, Vij R, DiPersio JF, Achilefu S, Azab AK. Federico C, et al. Among authors: azab ak. Nat Commun. 2020 Nov 27;11(1):6037. doi: 10.1038/s41467-020-19932-1. Nat Commun. 2020. PMID: 33247158 Free PMC article.
PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma.
Muz B, Buggio M, Azab F, de la Puente P, Fiala M, Padval MV, Weaver DT, Pachter JA, Vij R, Azab AK. Muz B, et al. Among authors: azab ak. Haematologica. 2019 Jul;104(7):e310-e313. doi: 10.3324/haematol.2018.194688. Epub 2019 Jan 17. Haematologica. 2019. PMID: 30655367 Free PMC article. No abstract available.
Biological Insights into Myeloma and Other B Cell Malignancies.
Fulciniti M, Amodio N, Cea M, Maiso P, Azab AK. Fulciniti M, et al. Among authors: azab ak. Biomed Res Int. 2016;2016:5218093. doi: 10.1155/2016/5218093. Epub 2016 Feb 16. Biomed Res Int. 2016. PMID: 26989685 Free PMC article. No abstract available.
Delivery systems for brachytherapy.
de la Puente P, Azab AK. de la Puente P, et al. Among authors: azab ak. J Control Release. 2014 Oct 28;192:19-28. doi: 10.1016/j.jconrel.2014.06.057. Epub 2014 Jul 5. J Control Release. 2014. PMID: 25008970 Review.
79 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page